BioSpace News Archive

MIVI Neuroscience, Inc. announced that it has enrolled the first patient in the Food and Drug Administration approved Investigational Device Exemption EVAQ Clinical Study.

BeiGene, Ltd., a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, announced the pricing of an underwritten public offering of 1,511,546 American Depositary Shares, each representing 13 of its ordinary shares, par value $0.0001 per share, by fund partnerships affiliated with Baker Bros.

Cogent Biosciences, Inc., a biotechnology company focused on developing precision therapies for genetically defined diseases, announced the pricing of an underwritten public offering of 10,256,411 shares of its common stock, offered at a public offering price of $9.75 per share.

Systemic effects observed in multiple patients, including two examples where a non-injected lesion completely regressed

Protagonist Therapeutics, Inc. reported that on November 30, 2020, it issued an inducement award to Michelle Landolfi, Ph.D., the Company’s recently hired Vice President, Regulatory Affairs, in accordance with the terms of Dr. Landolfi’s employment offer letter.

ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that on November 30, 2020 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 51,500 shares of its common stock to three new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan.

Leaders of Wisconsin’s two medical schools have an urgent message to the public: Right now, every person in the state has the power to save lives by choosing to take a stand against COVID-19.

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the initiation of the Phase 3 BALANCE study for AKCEA-APOCIII-LRx in adult patients with familial chylomicronemia syndrome (FCS). FCS is a debilitating genetic disease characterized by severely high plasma levels of triglycerid

Ocugen, Inc. announced that Institutional Shareholder Services Inc. and Glass, Lewis & Co., LLC, the nation’s leading independent proxy advisory firms, have recommended that Ocugen stockholders vote “FOR” both Proposals 1 and 2 at the Company’s Annual Meeting of Stockholders to be held on December 11, 2020.

Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved a Phase IIa clinical study of the company’s novel MDM2-p53 inhibitor APG-115,